Pancreatic Adenocarcinoma Management

Yan Jiang1, Davendra P S Sohal1

  • 1University of Cincinnati, Cincinnati, OH.

JCO Oncology Practice
|September 22, 2022
PubMed
Summary

Pancreatic ductal adenocarcinoma (PDAC) management now emphasizes neoadjuvant therapy to improve surgical outcomes. Advances include FOLFIRINOX, gemcitabine with nab-paclitaxel, and targeted therapies for select patients.